Based on novel gene fusions involving NRG1 that we recently discovered in a series of patients with KRAS wild-type pancreatic tumors (Heining et al. 2018) in the context of NCT/DKTK MASTER (Horak et al. 2017), a HTS-guided precision oncology program, we applied Arriba to further explore the relevance of gene fusions in pancreatic cancer. The gene discussed is KRAS; the disease is pancreatic neoplasm.